|
Overview |
Product information |
Accredo services |
Contact team
MPS I is a progressive, debilitating, and often life-threatening disease. It is an inherited disorder caused by a deficiency of an enzyme called alpha-L-iduronidase. This enzyme is required for the breakdown of certain substances in the body commonly referred to as GAG (glycosaminoglycans). As more and more GAG builds up in a person's body, almost all organs can be irreversibly damaged. Therefore, early diagnosis and treatment of MPS I is important. MPS I has also been called Hurler, Hurler-Scheie, and Scheie Syndromes. Learn more about our Hurler-Scheie therapy management.
Accredo has been working with lysosomal storage disorder (LSD) therapies since 1991 and has gained extensive experience that serves as a valuable resource to our patients.
Referrals
Other Resources:
Aldurazyme.com
Genzyme Corporation
National MPS Society
NORD - National Organization for Rare Diseases
Aldurazyme is a registered trademark of Genzyme Corporation.
| 
